ClinicalTrials.gg
Sign In
CompletedNCT00334451Updated Feb 24, 2014

RAPID-RF: Remote Active Monitoring in Patients With Heart Failure

An observational study in Heart Failure, sponsored by Boston Scientific Corporation. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-24.

Sponsored by Boston Scientific Corporation · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
891
Ages
18 Years and older
Sex
All
01

Study summary

The RAPID-RF Registry aims to characterize LATITUDE® Patient Management's alert feature: LATITUDE Active Monitoring™ by evaluating type and frequency of alert notifications and alert-related medical interventions. This registry will also assess clinical outcomes including quality of life and New York Heart Association Class changes over time, mortality, hospitalizations and heart failure-related event rates.

02

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • Remote Monitoring
  • Implantable Device
03

In context

Heart Failure

5,803 studies on the registry are indexed under Heart Failure; 1,222 are open to participants now.

This study's enrollment of 891 is above the median of 200 across 1,719 observational studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Boston Scientific Corporation is the lead sponsor of 527 studies on the registry; 40 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 56 (88%) have results posted.

Browse Boston Scientific Corporation studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary care clinics, heart failure clinics, hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who meet current indications for a Guidant RF-enabled CRT-D device (e.g. CONTAK RENEWAL 3 RF family of CRT-D devices) which is compatible with the LATITUDE Communicator. Indications include: NYHA Class III, IV; EF of ≤ 35%; QRS duration of ≥ 120 ms; and optimized pharmacologic therapy
  • Patients who have an analog telephone line compatible with the LATITUDE Communicator. The LATITUDE Communicator must be placed within 8 feet of where they sleep for successful remote interrogations to occur.
  • Patients who receive the study components including the LATITUDE Communicator, weight scale, and blood pressure monitor
  • Patients who are willing and capable of providing informed consent prior to implant and willing to participate in the RAPID-RF Registry
  • Patients who remain in the clinical care of a RAPID-RF investigator at approved centers

Exclusion criteria

Exclusion Criteria:

  • Patients who are expected to receive a heart transplant during the course of the study
  • Patients who have received or who will receive a tricuspid valve prosthesis during the course of the study
  • Patients who have previously received an implantable cardiac resynchronization device (e.g., biventricular pacemaker or biventricular ICD)
  • Patients whose life expectancy is less than 12 months
  • Patients who are currently enrolled in another observational registry or investigational study that could directly impact the treatment or outcome of the RAPID-RF Registry. Contact Guidant's Clinical Application Research Study (CARS) department to determine eligibility.
  • Patients who are younger than 18 years of age
  • Patients who are pregnant or plan to become pregnant during the study
  • Patients who are unable or refuse to comply with the protocol requirements
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
891 participants (actual)
06

Study locations

1 site
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
07

References and documents

Publications

  • Saxon LA, Boehmer JP, Neuman S, Mullin CM. Remote Active Monitoring in Patients with Heart Failure (RAPID-RF): design and rationale. J Card Fail. 2007 May;13(4):241-6. doi: 10.1016/j.cardfail.2006.12.004. PubMed 17517341 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2006
First posted
Jun 7, 2006
Start
May 2006
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Last update
Feb 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00334451
Lead sponsor
Boston Scientific Corporation
Responsible party
Sponsor
First posted
Jun 7, 2006
Start date
May 2006
Primary completion
Jul 2008
Completion
Jul 2008
Last update
Feb 24, 2014

Study contacts

Leslie A Saxon, MD
principal investigator · University of Southern California
John P Boehmer, MD
principal investigator · Hershey Medical Center, Hershey, PA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Failure →

Other studies from this sponsor

Boston Scientific Corporation →

Start the discussion